Wall Street Zen Downgrades Sensus Healthcare (NASDAQ:SRTS) to Strong Sell

Sensus Healthcare (NASDAQ:SRTS) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

Several other equities research analysts have also recently issued reports on SRTS. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st. Citigroup reissued a “buy” rating on shares of Sensus Healthcare in a research report on Friday. Maxim Group lowered their price objective on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Finally, Alliance Global Partners assumed coverage on shares of Sensus Healthcare in a research report on Friday, March 6th. They issued a “buy” rating and a $7.50 price objective for the company. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Sensus Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.88.

Sensus Healthcare Price Performance

Shares of NASDAQ SRTS opened at $3.08 on Friday. The company has a market cap of $50.70 million, a P/E ratio of -6.55 and a beta of 1.19. Sensus Healthcare has a 1 year low of $2.82 and a 1 year high of $5.92. The firm has a 50-day simple moving average of $4.14 and a two-hundred day simple moving average of $4.16.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $3.39 million during the quarter, compared to analysts’ expectations of $5.32 million. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.41%.

Institutional Investors Weigh In On Sensus Healthcare

Large investors have recently modified their holdings of the business. Opes Wealth Management LLC bought a new stake in shares of Sensus Healthcare in the 3rd quarter valued at about $50,000. XTX Topco Ltd bought a new stake in shares of Sensus Healthcare in the 4th quarter valued at about $77,000. Jane Street Group LLC bought a new stake in shares of Sensus Healthcare in the 4th quarter valued at about $79,000. Mindset Wealth Management LLC raised its holdings in shares of Sensus Healthcare by 28.1% in the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Ingalls & Snyder LLC bought a new stake in shares of Sensus Healthcare in the 4th quarter valued at about $219,000. Institutional investors own 25.30% of the company’s stock.

Trending Headlines about Sensus Healthcare

Here are the key news stories impacting Sensus Healthcare this week:

• Positive Sentiment: Sensus said it has amicably resolved its commercial dispute with SkinCure Oncology, which could reduce legal uncertainty and support a more stable operating outlook. Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology
• Positive Sentiment: Management outlined a full-year profitability goal for 2026, saying new CPT codes are now taking effect and could improve reimbursement and demand trends. Sensus outlines full year profitability goal for 2026 as new CPT codes take effect
• Neutral Sentiment: Recent earnings-call coverage focused on management’s recovery narrative and operational commentary, but did not add materially new financial information beyond the quarter’s results. Sensus Healthcare Charts Recovery Path Amid Revenue Drop
• Negative Sentiment: First-quarter 2026 results showed revenue of about $3.4 million, well below the prior year’s $8.3 million, while EPS of $(0.16) missed estimates and margins remained negative, reinforcing concerns about the company’s near-term growth and profitability. Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.